Flibanserin
-
Molecular Structure
Detailed Description
Model NO.:167933-07-5
Product Name:Flibanserin
CAS No.:167933-07-5
Appearance:White Powder
Export Markets:Global
Polciy:Re-Shipping Policy
Delivery:5-7 Working Days Door to Door
Assay:99%
Payment:Western Union, Moneygram, Bank Transfer
Shipping Ways:EMS, TNT, FedEx, DHL, by Air, etc
Production Origin:China
Product Description
Product Name: Flibanserin
CAS No.: 167933-07-5
Molecular formula: C20H21F3N4O
Molecular weight: 390.4
Content: 98%
Packing: 1KG/Bag
Appearance: White powder
Grade: Pharmaceutical grade
Usage:adrug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD)
Catagory: Pharmaceutical raw material female sex enhance
Description:
HSDD is the most commonly reported form of female sexual dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related, psychiatric (e.g., depression) or other sexual condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to a complex interplay of these factors.
Flibanserin is a novel, non-hormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.
Applications:
A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited by others, but it's hit a potentially serious snag. The drug didn't boost women's desire any more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical trial results on its website today in advance of a committee meeting on Friday, when a panel of experts will vote whether or not to recommend approval of the drug called flibanserin. (The FDA usually follows the recommendations of its expert panels.) Although there was a slight increase in the number of sexually satisfying events flibanserin users had each month, the FDA staff who reviewed the results said the so-called response rate isn't "particularly compelling."
It's called the "little pink pill," a tiny tablet that could have a huge impact on treating female sexual dysfunction. If it's approved, it would become the first drug of its kind on the market.
We are a direct manufacturer with high quality and competitive price. We have the following SARMs manufactured,
Ostarine, MK-2866, Enobosarm
Enobosarm (Ostarine, MK-2866, GTx-024) - affects both muscle and bone, intended mainly for osteoporosis but also general treatment for andropause and reversing muscle sarcopenia in the elderly and for cachexia in cancer patients.
LGD-4033
Pharmacological profile similar to that of enobosarm, Ostarine, MK-2866
MK-677, Ibutamoren, secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
Andarine (S-4)
Partial agonist, intended mainly for treatment of benign prostatic hypertrophy
GW-501516
It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease
AICAR
AICAR acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
- Flibanserin